查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2155743

皮下注射PD-L1抗體市場：全球市場預測，2026-2032年

Subcutaneously Injected PD-L1 Antibody Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，皮下 PD-L1 抗體市場將成長至 32.4 億美元，複合年成長率為 11.12%。

主要市場統計數據
基準年 2025 15.5億美元
預計年份：2026年 17億美元
預測年份 2032 32.4億美元
複合年成長率 (%) 11.12%

皮下注射PD-L1抗體：概述

皮下注射PD-L1抗體作為一種新型的免疫腫瘤給藥方式，正引起廣泛關注。其臨床與操作意義在於，既能維持PD-L1路徑抑制的治療目標，又能將給藥方式從靜脈輸注轉變為更柔軟性、療程更短的治療方案。評估應著重於臨床等效性、給藥便利性、注射部位耐受性、患者選擇、治療環境要求以及與現有腫瘤治療流程的整合。

管理方法、證據和護理路徑的變化

主要的變化在於，給藥模式正朝著減少輸液椅使用、支持更貼近患者進行治療的方向發展。其實施取決於能否提供證據證明藥物暴露量、療效、安全性、免疫抗原性以及與聯合治療的兼容性。相關人員還需要考慮設備性能、準備要求、觀察方案、報銷規則、培訓以及局部反應的處理。這些因素將決定皮下給藥究竟只是一種替代途徑，還是代表癌症治療體系的重大改變。

人工智慧如何促進開發和交付

人工智慧可以透過改進患者分層、識別與療效和免疫相關毒性相關的生物標記，以及幫助研究人員設計更高效的臨床試驗，為該領域提供支援。在生產製造和品管方面，機器學習工具可以輔助進行流程監控、異常檢測和供應鏈規劃。在醫療保健領域，臨床決策支援可以幫助識別適合皮下給藥的患者、預測不利事件並改善追蹤。由於模型性能取決於具有代表性的數據、透明的檢驗以及防止偏差和不恰當臨床建議的安全措施，因此人工監督仍然至關重要。

六個醫療保健環境的區域洞察

北美地區擁有完善的腫瘤治療基礎設施、積極的生物製藥研發，並高度重視減輕靜脈給藥的負擔，但支付方政策和醫療服務地點的經濟狀況仍然是重要因素。歐洲則兼具完善的癌症治療網路和各國特有的評估、報銷和採購要求。亞太地區的管理體制、治療能力和准入條件高度多樣化，這為引入靈活給藥模式提供了機遇，但實際執行情況存在顯著差異。拉丁美洲的優勢在於對設施和人員的需求較低，但在准入、經濟負擔和診斷能力方面存在差異。中東地區集中了許多專業醫療服務機構，並大力投資於現代化的腫瘤治療基礎設施，而非洲在廣泛實施前，需要仔細考慮冷鏈可靠性、人力資源可用性、診斷支持和公平准入等問題。

來自東協、金磚國家、歐盟、七國集團、海灣合作理事會和北約的集團層級趨勢

東協的監管和醫療環境多元化，因此統一的證據包和靈活的服務模式至關重要。金磚國家擁有強大的研發、生產和醫療服務能力，但在報銷、本地生產和取得途徑方面存在顯著差異。歐盟強調協調一致的監管科學，同時在衛生技術評估和支付方面保持國家差異。七國集團（G7）體系通常將成熟的腫瘤學專業知識與提高效率和患者便利性的壓力相結合。海灣合作理事會（GCC）市場的特點是集中採購系統和資源充足的專科醫療中心，這有利於在證據和報銷機制一致的情況下進行快速評估。北約並非醫療市場，但在其成員國重疊區域，彈性供應鏈、協調的準備工作以及可靠的基本生物製藥取得途徑至關重要。

針對不同國家的開發和實施考量因素

澳洲和加拿大已建立完善的臨床研究和公共衛生體系，但其實施受到國家醫保報銷機制和地理可近性的影響。巴西和墨西哥必須在專科醫療中心的容量、區域差異和預算限制之間取得平衡。中國和印度擁有龐大的患者群體和不斷增強的生物製藥研發能力，但在監管、定價和可及性方面面臨複雜的考量。日本和韓國擁有先進的癌症治療基礎設施，人們對實證醫學、醫療品質和工作流程效率寄予厚望。法國、德國、義大利、西班牙和英國均提供先進的癌症治療，但在評估、採購和區域實施方面存在差異。俄羅斯在監管、供應和醫療保健體系方面有其獨特的考量，需要進行細緻的本地評估。美國擁有廣泛的臨床專業知識和多元化的醫療服務體系，但有關保險覆蓋範圍和地理位置的政策可能會顯著影響治療的可及性。

行業領導者的優先事項

領導者應透過與已建立的靜脈注射方法進行直接比較來累積證據。這應包括患者療效、藥物動力學、免疫抗原性、安全性、治療完成率、臨床治療時間。研發計劃應反映患者和臨床醫生對注射體驗、就診頻率、給藥物流以及與聯合治療相容性的回饋。商業和准入部門應儘早了解各國特定的監管、報銷、採購和藥物技術評估要求。各組織也應建立完善的生產和冷鏈流程，檢驗給藥裝置和培訓材料，並利用真實世界數據監測上市後的依從性、當地耐受性、資源利用和健康公平性。

高階主管評估調查方法

本評估針對皮下注射PD-L1抗體市場，並系統性地分析了給藥方式創新、臨床證據、人工智慧、區域因素和相關人員群體等方面的解讀。此方法優先考慮檢驗的監管、臨床、醫療保健系統和部署訊息，而非未經證實的商業性假設。區域和國家層面的比較考慮了腫瘤基礎設施、生物製藥處理能力、給藥途徑、報銷方案、人力資源和供應鏈狀況。由於本評估不包含檢驗的定量資料集，因此本摘要有意省略了市場估算、預測、市場佔有率、展望和公司特定聲明。

結論：證據和實施情況決定臨床價值。

皮下注射PD-L1抗體可望提高治療便利性，減輕以靜脈注射為主的腫瘤治療服務負擔，但其價值並非完全取決於給藥途徑。負責任地推廣應用需要強力的對比研究、可靠的生產流程、合適的患者選擇、切實可行的保險報銷以及社區協作的治療路徑。將嚴謹的臨床實踐與完善的推廣規劃、數位化支持以及對跨區域公平性的考慮相結合的行業領導者，將更有能力判斷這種方法在哪些領域能夠帶來顯著的益處。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 皮下注射PD-L1抗體市場：依治療階段分類

  • 一線治療
  • 第二行
  • 從第三行開始

第8章 皮下注射PD-L1抗體市場：以劑型分類

  • 自動噴油器
  • 預填充式注射器

第9章 皮下注射PD-L1抗體市場：依適應症分類

  • 頭頸癌
  • 黑色素瘤
    • 一線治療
    • 第二行
    • 從第三行開始
  • 非小細胞肺癌
    • 一線治療
    • 二級治療
    • 從第三行開始
  • 腎臟細胞癌
  • 尿路上皮癌

第10章 皮下注射PD-L1抗體市場：依最終用戶分類

  • 門診部
  • 家庭醫療保健
  • 醫院
  • 專科診所

第11章 皮下注射PD-L1抗體市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 皮下注射PD-L1抗體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 皮下注射PD-L1抗體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • 3D Medicines Co., Ltd.
  • Agenus Inc.
  • Alphamab Oncology
  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • CStone Pharmaceuticals Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shanghai Henlius Biotech, Inc.
  • Simcere Pharmaceutical Group Limited
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • TRACON Pharmaceuticals, Inc.

第16章 主要專家

Product Code: MRR-537DB9F471AE

The Subcutaneously Injected PD-L1 Antibody Market is projected to grow by USD 3.24 billion at a CAGR of 11.12% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.55 billion
Estimated Year [2026] USD 1.70 billion
Forecast Year [2032] USD 3.24 billion
CAGR (%) 11.12%

Subcutaneously Injected PD-L1 Antibody: Executive Overview

Subcutaneously injected PD-L1 antibodies represent an emerging delivery approach within immuno-oncology. Their clinical and operational relevance is tied to modifying administration from intravenous infusion toward a potentially shorter, more flexible treatment experience, while preserving the therapeutic intent of PD-L1 pathway inhibition. Evaluation should focus on clinical comparability, dosing convenience, injection-site tolerability, patient selection, treatment-setting requirements, and integration with existing oncology workflows.

Administration, Evidence, and Care-Pathway Shifts

The principal landscape shift is the movement toward administration models that may reduce infusion-chair use and support treatment closer to patients. Adoption depends on evidence demonstrating consistent exposure, efficacy, safety, immunogenicity, and compatibility with combination regimens. Stakeholders must also address device performance, preparation requirements, observation protocols, reimbursement rules, training, and the management of local reactions. These factors will determine whether subcutaneous delivery is merely an alternative route or a meaningful redesign of cancer care delivery.

How Artificial Intelligence Can Strengthen Development and Delivery

Artificial intelligence can support this field by improving patient stratification, identifying biomarkers associated with response or immune-related toxicity, and helping researchers design more efficient clinical studies. In manufacturing and quality operations, machine-learning tools may assist process monitoring, anomaly detection, and supply-chain planning. In care delivery, clinical decision support can help identify candidates for subcutaneous administration, anticipate adverse events, and improve follow-up. Human oversight remains essential because model performance depends on representative data, transparent validation, and safeguards against biased or clinically inappropriate recommendations.

Regional Insights Across Six Care Environments

North America is characterized by advanced oncology infrastructure, active biologic development, and strong interest in reducing infusion burden, although payer policies and site-of-care economics remain important. Europe combines sophisticated cancer networks with country-specific assessment, reimbursement, and procurement requirements. Asia-Pacific includes highly varied regulatory systems, treatment capacity, and access conditions, creating opportunities for flexible administration models alongside substantial implementation differences. Latin America may benefit from reduced facility and staffing demands but faces uneven access, affordability, and diagnostic capacity. The Middle East is shaped by concentrated specialist services and investment in modern oncology infrastructure, while Africa requires careful attention to cold-chain reliability, workforce capacity, diagnostic support, and equitable access before broad deployment.

Group-Level Signals from ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN presents diverse regulatory and healthcare environments, making harmonized evidence packages and adaptable delivery models valuable. BRICS countries span major research, manufacturing, and care-delivery capabilities but differ considerably in reimbursement, local production, and access conditions. The European Union places emphasis on coordinated regulatory science while retaining national variation in health-technology assessment and payment. G7 systems generally combine mature oncology expertise with pressure to improve productivity and patient convenience. GCC markets often feature centralized purchasing and well-resourced specialist centers, supporting rapid evaluation where evidence and reimbursement align. NATO is not a healthcare market, but its member-country overlap highlights the importance of resilient supply chains, coordinated preparedness, and secure access to essential biologic therapies.

Country-Level Considerations for Development and Adoption

Australia and Canada offer established clinical research and public health systems, with adoption influenced by national reimbursement and geographic access. Brazil and Mexico must balance specialist-center capacity with regional inequities and budget sensitivity. China and India combine substantial patient populations and expanding biopharmaceutical capabilities with complex regulatory, pricing, and access considerations. Japan and South Korea have advanced oncology infrastructure and strong expectations for evidence, quality, and workflow efficiency. France, Germany, Italy, Spain, and the United Kingdom each provide sophisticated cancer care but differ in assessment, procurement, and regional implementation. Russia presents distinct regulatory, supply, and healthcare-system considerations that require careful local evaluation. The United States offers extensive clinical expertise and diverse delivery settings, while coverage and site-of-care policies can materially shape use.

Priorities for Industry Leaders

Leaders should generate head-to-head evidence against established intravenous administration, including patient outcomes, pharmacokinetics, immunogenicity, safety, treatment completion, and time spent in care settings. Development plans should incorporate patient and clinician input on injection experience, visit frequency, administration logistics, and combination-treatment compatibility. Commercial and access teams should map country-specific regulatory, reimbursement, procurement, and health-technology assessment requirements early. Organizations should also build resilient manufacturing and cold-chain processes, validate administration devices and training materials, and use real-world data to monitor adherence, local tolerability, resource use, and health equity after introduction.

Research Methodology for the Executive Assessment

This assessment uses the defined market scope of subcutaneously injected PD-L1 antibody and organizes interpretation across delivery innovation, clinical evidence, artificial intelligence, geography, and stakeholder groups. The approach prioritizes verified regulatory, clinical, health-system, and implementation information rather than unsupported commercial assumptions. Regional and country comparisons consider oncology infrastructure, biologic-handling capability, access pathways, reimbursement, workforce, and supply-chain conditions. Because the scope does not provide validated quantitative datasets, this summary intentionally excludes market estimates, market shares, forecasts, and company-specific claims.

Conclusion: Evidence and Implementation Will Shape Clinical Value

Subcutaneous PD-L1 antibody delivery has the potential to improve convenience and reduce pressure on infusion-based oncology services, but its value depends on more than route of administration. Robust comparative evidence, reliable manufacturing, appropriate patient selection, practical reimbursement, and locally workable care pathways are necessary for responsible adoption. Industry leaders that combine clinical rigor with implementation planning, digital support, and attention to regional equity will be better positioned to determine where this approach can deliver meaningful benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Subcutaneously Injected PD-L1 Antibody Market, by Line Of Therapy

  • 7.1. Introduction
  • 7.2. First Line
  • 7.3. Second Line
  • 7.4. Third Line And Beyond

8. Subcutaneously Injected PD-L1 Antibody Market, by Delivery Format

  • 8.1. Introduction
  • 8.2. Autoinjector
  • 8.3. Prefilled Syringe

9. Subcutaneously Injected PD-L1 Antibody Market, by Indication

  • 9.1. Introduction
  • 9.2. Head And Neck Cancer
  • 9.3. Melanoma
    • 9.3.1. First Line
    • 9.3.2. Second Line
    • 9.3.3. Third Line And Beyond
  • 9.4. Non-Small Cell Lung Cancer
    • 9.4.1. First Line
    • 9.4.2. Second Line
    • 9.4.3. Third Line And Beyond
  • 9.5. Renal Cell Carcinoma
  • 9.6. Urothelial Carcinoma

10. Subcutaneously Injected PD-L1 Antibody Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Care Center
  • 10.3. Home Healthcare
  • 10.4. Hospital
  • 10.5. Specialty Clinic

11. Subcutaneously Injected PD-L1 Antibody Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Subcutaneously Injected PD-L1 Antibody Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Subcutaneously Injected PD-L1 Antibody Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. 3D Medicines Co., Ltd.
  • 15.2. Agenus Inc.
  • 15.3. Alphamab Oncology
  • 15.4. AstraZeneca PLC
  • 15.5. Bristol Myers Squibb Company
  • 15.6. CStone Pharmaceuticals Co., Ltd.
  • 15.7. F. Hoffmann-La Roche AG
  • 15.8. GlaxoSmithKline plc
  • 15.9. Glenmark Pharmaceuticals Ltd.
  • 15.10. Halozyme Therapeutics, Inc.
  • 15.11. Incyte Corporation
  • 15.12. Innovent Biologics, Inc.
  • 15.13. Merck KGaA
  • 15.14. Pfizer Inc.
  • 15.15. Regeneron Pharmaceuticals, Inc.
  • 15.16. Shanghai Henlius Biotech, Inc.
  • 15.17. Simcere Pharmaceutical Group Limited
  • 15.18. Suzhou Zelgen Biopharmaceuticals Co., Ltd.
  • 15.19. TRACON Pharmaceuticals, Inc.

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Subcutaneously Injected PD-L1 Antibody Market, Years Considered for the Study
  • FIGURE 2. Global Subcutaneously Injected PD-L1 Antibody Market, Research Design
  • FIGURE 3. Global Subcutaneously Injected PD-L1 Antibody Market, Research Framework
  • FIGURE 4. Global Subcutaneously Injected PD-L1 Antibody Market, Data Triangulation
  • FIGURE 5. Global Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2025 vs 2032 (%)
  • FIGURE 7. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2025 vs 2032 (%)
  • FIGURE 9. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 11. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Subcutaneously Injected PD-L1 Antibody Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Subcutaneously Injected PD-L1 Antibody Market Segmentation & Coverage
  • TABLE 2. Global Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 4. Global First Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global First Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global First Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 14. Global Autoinjector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Autoinjector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Autoinjector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 21. Global Head And Neck Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global Head And Neck Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global Head And Neck Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global First Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global First Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global First Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Non-Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Non-Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Non-Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global First Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global First Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global First Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Renal Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Renal Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Renal Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Urothelial Carcinoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Urothelial Carcinoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Urothelial Carcinoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 55. Global Ambulatory Care Center Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Ambulatory Care Center Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Ambulatory Care Center Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 70. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 72. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 73. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 74. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 75. North America Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. North America Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 77. North America Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 78. North America Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 79. North America Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 80. North America Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 81. North America Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 82. Latin America Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Latin America Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 84. Latin America Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 85. Latin America Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 86. Latin America Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 87. Latin America Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 88. Latin America Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 89. Europe Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Europe Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 91. Europe Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 92. Europe Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 93. Europe Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 94. Europe Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 95. Europe Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 96. Middle East Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Middle East Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 98. Middle East Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 99. Middle East Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 100. Middle East Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 101. Middle East Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 102. Middle East Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 103. Africa Subcutaneously Injected PD-L1 Antibody Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Africa Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 105. Africa Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 106. Africa Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 107. Africa Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 108. Africa Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 109. Africa Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 110. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 111. ASEAN Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. ASEAN Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 113. ASEAN Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 114. ASEAN Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 115. ASEAN Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 116. ASEAN Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 117. ASEAN Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 118. GCC Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. GCC Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 120. GCC Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 121. GCC Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 122. GCC Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 123. GCC Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 124. GCC Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 125. European Union Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 126. European Union Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 127. European Union Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 128. European Union Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 129. European Union Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 130. European Union Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 131. European Union Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 132. BRICS Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 133. BRICS Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 134. BRICS Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 135. BRICS Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 136. BRICS Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 137. BRICS Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 138. BRICS Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 139. G7 Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 140. G7 Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 141. G7 Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 142. G7 Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 143. G7 Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 144. G7 Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 145. G7 Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 146. NATO Subcutaneously Injected PD-L1 Antibody Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. NATO Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 148. NATO Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 149. NATO Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 150. NATO Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 151. NATO Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 152. NATO Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 153. Global Subcutaneously Injected PD-L1 Antibody Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 154. United States Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 155. United States Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 156. United States Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 157. United States Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 158. United States Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 159. United States Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 160. United States Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 161. Canada Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 162. Canada Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 163. Canada Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 164. Canada Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 165. Canada Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 166. Canada Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 167. Canada Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 168. Mexico Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 169. Mexico Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 170. Mexico Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 171. Mexico Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 172. Mexico Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 173. Mexico Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 174. Mexico Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Brazil Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 176. Brazil Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 177. Brazil Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 178. Brazil Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 179. Brazil Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 180. Brazil Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 181. Brazil Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 182. United Kingdom Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 183. United Kingdom Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 184. United Kingdom Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 185. United Kingdom Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 186. United Kingdom Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 187. United Kingdom Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 188. United Kingdom Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 189. Germany Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 190. Germany Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 191. Germany Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 192. Germany Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 193. Germany Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 194. Germany Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 195. Germany Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 196. France Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 197. France Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 198. France Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 199. France Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 200. France Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 201. France Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 202. France Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 203. Russia Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 204. Russia Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 205. Russia Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 206. Russia Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 207. Russia Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 208. Russia Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 209. Russia Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 210. Italy Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 211. Italy Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 212. Italy Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 213. Italy Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 214. Italy Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 215. Italy Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 216. Italy Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 217. Spain Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 218. Spain Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 219. Spain Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 220. Spain Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 221. Spain Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 222. Spain Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 223. Spain Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 224. China Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 225. China Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 226. China Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 227. China Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 228. China Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 229. China Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 230. China Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 231. India Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 232. India Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 233. India Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 234. India Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 235. India Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 236. India Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 237. India Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 238. Japan Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 239. Japan Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 240. Japan Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 241. Japan Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 242. Japan Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 243. Japan Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 244. Japan Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 245. Australia Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 246. Australia Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 247. Australia Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 248. Australia Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 249. Australia Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 250. Australia Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 251. Australia Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 252. South Korea Subcutaneously Injected PD-L1 Antibody Market Size, 2017-2032 (USD Million)
  • TABLE 253. South Korea Subcutaneously Injected PD-L1 Antibody Market Size, by Line Of Therapy, 2017-2032 (USD Million)
  • TABLE 254. South Korea Subcutaneously Injected PD-L1 Antibody Market Size, by Delivery Format, 2017-2032 (USD Million)
  • TABLE 255. South Korea Subcutaneously Injected PD-L1 Antibody Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 256. South Korea Subcutaneously Injected PD-L1 Antibody Market Size, by Melanoma, 2017-2032 (USD Million)
  • TABLE 257. South Korea Subcutaneously Injected PD-L1 Antibody Market Size, by Non-Small Cell Lung Cancer, 2017-2032 (USD Million)
  • TABLE 258. South Korea Subcutaneously Injected PD-L1 Antibody Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 259. Global Subcutaneously Injected PD-L1 Antibody Market Share, by Key Player, 2025
  • TABLE 260. Global Subcutaneously Injected PD-L1 Antibody Market, Key Experts